Rekambys Drug Use Results Survey

Rekambys Drug Use Results Survey - Rekambys Drug Use Results Survey

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051600

Enrollment

140

Registered

2023-07-15

Start date

2022-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with HIV infection who administrated Rekambys

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (ADR) Effectiveness(Changes in HIV-RNA level, Changes in CD4 lymphocyte count)	—

Countries

Japan

Contacts

Public ContactKazuyo Izumiya

Post-approval Delivary Unit Janssen Pharmaceutical K.K. Post-approval Delivary Unit

kizumiya@its.jnj.com03-4411-5031

Outcome results